论文部分内容阅读
目的 :观察在常规治疗基础上加用银杏酮酯分散片治疗缺血性脑卒中患者的效果。方法 :选取本院收治的80例血瘀型缺血性脑卒中患者作为研究对象,随机分为观察组与对照组各40例,2组患者入院后均给予常规治疗,观察组在此基础上给予银杏酮酯分散片治疗,对照组给予阿司匹林肠溶片治疗,以1周为1疗程,连续治疗2疗程。观察比较2组的临床疗效;治疗前后对2组患者的血液流变学指标(全血黏度、血浆黏度、纤维蛋白原、红细胞压积)进行测定,评价美国国立卫生院神经功能缺损评分(NIHSS)、简易精神状态评价量表(MMSE)评分;随访6月,对2组患者的病情复发情况进行统计。结果:观察组总有效率90.0%,优于对照组的67.5%,2组比较,差异有统计学意义(P<0.05)。2组全血黏度、血浆黏度、纤维蛋白原、红细胞压积较治疗前均下降(P<0.05),观察组各项指标值均低于对照组(P<0.05)。2组NIHSS、MMSE评分较治疗前均有改善(P<0.05),观察组NIHSS低于对照组,MMSE评分高于对照组,差异均有统计学意义(P<0.05)。观察组复发率为0,对照组复发率为26.7%,2组复发率比较,差异有统计学意义(P<0.05)。结论:在常规治疗基础上加用银杏酮酯分散片治疗血瘀型缺血性脑卒中患者临床疗效显著,可有效改善患者的血液流变学指标、神经功能缺损程度和认知功能障碍,对脑卒中可起到二级预防作用。
Objective: To observe the effect of adding Ginkgo biloba ester dispersible tablets on patients with ischemic stroke on the basis of routine treatment. Methods: Eighty patients with ischemic stroke with blood stasis syndrome admitted to our hospital were enrolled in this study. They were randomly divided into observation group (40 cases) and control group (40 cases). Both groups were given routine treatment after admission. On the basis of this observation group Give Ginkgo biloba ester dispersible tablets treatment, the control group given aspirin enteric-coated tablets treatment, 1 week for a course of treatment, continuous treatment 2 courses. The clinical curative effect of the two groups were observed and compared. The hemorheology indexes (whole blood viscosity, plasma viscosity, fibrinogen and hematocrit) of two groups were measured before and after treatment to evaluate the neurological deficit score of the National Institutes of Health (NIHSS ), Simple mental state evaluation scale (MMSE) score; followed up for 6 months, the two groups of patients with recurrent disease statistics. Results: The total effective rate in the observation group was 90.0%, which was better than 67.5% in the control group. There was significant difference between the two groups (P <0.05). The whole blood viscosity, plasma viscosity, fibrinogen, and hematocrit of the two groups decreased compared with those before treatment (P <0.05). The indexes in the observation group were lower than those in the control group (P <0.05). The scores of NIHSS and MMSE were improved in both groups (P <0.05). The NIHSS in the observation group was lower than that in the control group, and the MMSE score was higher than that in the control group. The difference was statistically significant (P <0.05). The recurrence rate was 0 in the observation group and 26.7% in the control group, and the recurrence rate in the two groups was statistically significant (P <0.05). Conclusion: The clinical curative effect of adding Ginkgo biloba ester dispersible tablets on ischemic stroke patients with blood stasis is significant, which can effectively improve the hemorrheological indexes, the degree of neurological deficits and cognitive dysfunction in patients. Stroke can play a secondary role in prevention.